Philadelphia, Pennsylvania 19004


Purpose:

The study is a prospective, observational, case-control study evaluating the utility of endoscopic ultrasound for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2 mutations.


Criteria:

Inclusion Criteria: - Informed consent provided - Age greater than or equal to 18 Patients: - Able and willing to attend routine follow-up as advised BRCA2 Mutation Carriers - Patients with a history of BRCA2 Mutation, with or without manifestation of breast or ovarian cancer, over the age of 50. - Any BRCA2 patient who has a first degree or 2 second degree family members with a history or pancreatic cancer will initiate screening 10 years prior to the age of onset of the index pancreatic neoplasia. BRCA1, ATM, & PALB2 Mutation Carriers - Any BRCA1 patient who has a first degree or 2 second degree family members with a history or pancreatic cancer will initiate screening 10 years prior to the age of onset of the index pancreatic neoplasia. Exclusion Criteria: - Known infection with HIV, HBC, or HCV - Pregnancy Esophageal strictures prior to treatment - Zenkers Diverticulum prior to treatment - History of abnormal or post surgical (i.e. post-Roux-en-Y Gastric Bypass) foregut anatomy precluding endoscopic ultrasound examination of the pancreas.


NCT ID:

NCT02478892


Primary Contact:

Anil Rustgi, MD
Phone: 855-216-0098
Email: PennCancerTrials@emergingmed.com


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19004
United States

Anil Rustgi, MD
Phone: 855-216-0098
Email: PennCancerTrials@emergingmed.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.